Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities [3]

Journal of Medicinal Chemistry

Volumn 42, Issue 16, 1999, Pages 3018-3022

  Bom, David ^a   Curran, Dennis P ^a   Chavan, Ashok J ^b   Kruszewski, Stefan ^c   Zimmer, Stephen G ^d,e   Fraley, Kimberly A ^c   Burke, Thomas G ^b,c,e,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Tigen Pharmaceuticals Inc   (United States)

^c University of Kentucky   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; GYRASE INHIBITOR; TOPOTECAN;

DRUG DESIGN; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; LETTER; LIPID BILAYER; LIPOPHILICITY;

CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DNA TOPOISOMERASES, TYPE I; DRUG STABILITY; ENZYME INHIBITORS; FLUORESCENCE POLARIZATION; HUMANS; HYDROLYSIS; PHOSPHATIDYLGLYCEROLS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033549870     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902279     Document Type: Letter

References (23)

1. Slichenmeyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. The Current Status of Camptothecin Analogues as Anticancer Agents. J. Natl. Cancer Inst. 1993, 85, 271.
2. Takimoto, C. H.; Arbuck, S. G. The Camptothecins. In Cancer Chemotherapy and Biotherapy, 2nd ed.; Chabner, B. A., Longo, D. A., Eds.; Lippincott-Raven Publishers: Philadelphia, 1996.
3. Giovanella, B. C.; Stehlin, J. S.; Wall, M. C.; Nicholas, A. W.; Liu, L. F.; Silber, R.; Potmesil, M. DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenograft. Science 1989, 246, 1046-1048.
4. Fassberg, J.; Stella, V. J. A Kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogues. J. Pharm. Sci. 1992, 81, 676-684.
5. Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. On the Mechanism of Topoisomerase Inhibition by Camptothecin: Evidence for Binding to an Enzyme-DNA Complex. Biochemistry 1989, 28, 4629-4638.
6. Hsiang, Y.-H.; Liu, L. F. Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin. Cancer Res. 1988, 48, 1722-1726.
7. Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E.; Pommier, Y. Structure - Activity Study of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity. Cancer Res. 1989, 49, 5077-5082.
8. Burke, T. G.; Mi, Z. Preferential Binding of the Carboxylate Form of Camptothecin by Human Serum Albumin. Anal. Biochem. 1993, 212, 285-287.
9. Burke, T. G.; Mi, Z. The Structural Basis of Camptothecin Interactions with Human Serum Albumin: Impact on Drug Stability. J. Med. Chem. 1994, 37, 40-46.
10. Mi, Z.; Burke, T. G. Differential interactions of Camptothecin Lactone and Carboxylate Forms with Human Blood Components. Biochemistry 1994, 33, 10325-10336.
11. Mi, Z.; Burke, T. G. Marked Interspecies Variations Concerning the Interactions of Camptothecin with Serum Albumins: A Frequency-Domain Fluorescence Spectroscopic Study. Biochemistry 1994, 33, 12540-12545.
12. Burke, T. G.; Mi, Z.; Jiang, Y.; Munshi, C. B. The Important Role of Albumin in Determining the Relative Human Blood Stabilities of the Camptothecin Anticancer Drugs. J. Pharm. Sci. 1995, 84, 518-519.
13. Mi, Z.; Malak, H.; Burke, T. G. Reduced Albumin Binding Promotes the Stability and Activity of Topotecan in Human Blood. Biochemistry 1995, 34, 13722-13728.
14. Burke, T. G.; Staubus, A. E.; Mishra, A. K.; Malak, H. Liposomal Stabilization of Camptothecin's Lactone Ring. J. Am. Chem, Soc. 1992, 114, 8318-8319.
15. Burke, T. G.; Mishra, A. K.; Wani, M.; Wall, M. Lipid Bilayer Partitioning and Stability of Camptothecin Drugs. Biochemistry 1993, 32, 5352-5364.
16. O'Connor, P. M.; Kerrigan, D.; Bertrand, R.; Kohn, K. W.; Pommier, Y. 10, 11-Methylenedioxycamptothecin, A Topoisomerase Inhibitor of Increased Potency: DNA Damage and Correlation to Cytotoxicity in Human Colon Carcinoma (HT-29) Cells. Cancer Commun. 1990, 2, 395-400.
17. Lavergne, O.; Lesueur-Ginot, L.; Rodas, F. P.; Kasprzyk, P. G.; Pommier, J.; Demarquay, D.; Prevost, G.; Ulibarri, G.; Rolland, A.; Schiano-Liberatore, A.-M.; Harnett, J.; Pons, D.; Camara, J.; Bigg, D. Homocamptothecins: Synthesis and Antitumor Activity of Novel E-Ring Modified Camptothecin Analogues. J. Med. Chem. 1998, 41, 5410-5419.
18. Lavergne, O.; Lesueur-Ginot, L.; Rodas, F. P.; Bigg, D. An E-Ring Modified Camptothecin With Potent Antiproliferative and Topoisomerase I inhibitory Activities. Bioorg. Med. Chem. Lett. 1997, 7, 2235-2238.
19. Curran, D. P.; Ko, S. B.; Josien, H. Cascade Radical Reactions of Isonitriles: A Second-generation Synthesis of (20S)-camp-tothecin, Topotecan, Irinotecan, and GI-147211C. Angew. Chem., Int. Ed. Engl. 1995, 34, 2683-2684.
20. Josien, H.; Ko, S. B.; Bom, D.; Curran, D. P. A general synthetic approach to the (20S)-camptothecin family of antitumor agents by a regiocontrolled cascade radical cyclization of aryl isonitriles. Chem. Eur. J. 1998, 4, 67-83.
21. Hochberg, F.; Grossman, S. A.; Mikkelsen, T.; Calabresi, P.; Fisher, J.; Piantadosi, S. For The NABTT CNS Consortium, Baltimore, MD. Efficacy of 9-aminocamptothecin (9-AC) in adults with newly diagnosed glioblastoma multiforme (GBM) and recurrent high grade astrocytomas (HGA). Proc. Am. Soc. Clin. Oncol. 1998, 17, 388a.
22. The cytotoxic potency of each homosilatecan against MDA-MB-435 human breast carcinoma cells was determined for 72-h exposure times. Sulforhodamine viability assays were used in the measurements.
23. Josien, H.; Bom, D.; Curran, D. P.; Zheng, Y.-H.; Chou, T.-C. 7-Silylcamptothecins (Silatecans): A New Family of Camp-tothecin Antitumor Agents. Bioorg. Med. Chem. Lett. 1997, 7, 3189-3194.